ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
22 announcements
ALPA Laboratories Limited has intimated a board meeting on 14 November 2026 to consider unaudited standalone and consolidated half-yearly results for the period ended September 2026. Trading window is closed from 1 October 2026 until 48 hours after results announcement.
Alpa Laboratories filed its quarterly shareholding pattern for the period ended 30 September 2026 under Regulation 31(1)(b). This is a periodic statutory disclosure with no transaction.
Alpa Laboratories Ltd has submitted its quarterly shareholding pattern under Regulation 31(1)(b) of the SEBI Listing Regulations for the period ended September 30, 2026.
Alpa Laboratories shareholders approved seven resolutions at the AGM, including a Rs. 160 Crore limit for loans and investments. All ordinary and special resolutions were passed.
Alpa Laboratories Ltd. held its 38th AGM on September 30, 2026. Shareholders approved financial statements, director appointments, auditor remuneration, and investment limits under Section 186.
Alpa Laboratories Ltd has appointed Ms. Diksha Jaswani as the Company Secretary and Compliance Officer (KMP), effective September 17, 2026.
Alpa Laboratories Ltd. has submitted its Annual Report for FY 2025-26 and the Notice for its 38th Annual General Meeting scheduled for September 30, 2026.
Alpa Laboratories will close its transfer register from 23 to 30 Sept 2026 for the 38th AGM. This is a routine book-closure intimation under Regulation 42 with no financial impact.
Alpa Laboratories appointed Mrs. Radhika Biyani as an Additional Independent Director, effective 5 September 2026. Board committees were reconstituted following the change.
Alpa Laboratories Ltd reported revenue from operations of ₹23.9 Cr (+25.1% YoY) and net profit of ₹1 Cr (-91.5% YoY) for Q1 FY27.
Alpa Laboratories Ltd. will hold a board meeting on August 13, 2026, to consider financial results for the quarter ended June 30, 2026, and approve the 38th AGM notice.
Alpa Laboratories Ltd. has approved exploring the incorporation of an overseas entity in Nigeria, 'Alpa Biopharm Limited,' in partnership with Blueseal Pharmaceuticals Limited. This is in-principle only.
Alpa Laboratories Limited clarified discrepancies in its revised consolidated financial results submitted in XBRL format. The update ensures Profit Before Tax figures align with previously signed statements.
Alpa Laboratories Limited announced the cessation of Ms. Jyoti Jain as a Non-Executive Independent Director upon the completion of her tenure, effective July 21, 2026.
Alpa Laboratories reports resignation of Company Secretary Yashoda Patidar, effective July 26, 2026. No further disclosures are required per the filing.
Alpa Laboratories Ltd reported revenue from operations of ₹31.4 Cr (-21.3% YoY) and net profit of ₹1.4 Cr for Q4 FY26.
Alpa Laboratories reported audited financial results for the year ended March 31, 2026. The board also appointed new internal and cost auditors for the upcoming fiscal year.
Alpa Laboratories Limited scheduled a board meeting for May 29, 2026, to approve audited yearly financial results. Trading remains closed until June 1, 2026.
Alpa Laboratories Limited has appointed Ms. Yashoda Patidar as Company Secretary and Compliance Officer, effective April 11, 2026. Ms. Patidar is an associate member of the Institute of Company Secretaries of India.
Alpa Laboratories Ltd has appointed Ms. Yashoda Patidar as Company Secretary and Compliance Officer, effective April 11, 2026. She succeeds the previous incumbent and is an Associate Member of the Institute of Company Secretaries of India.
Alpa Laboratories Limited has appointed Ms. Yashoda Patidar as Company Secretary and Compliance Officer, effective April 11, 2026. She is an Associate Member of the Institute of Company Secretaries of India. The appointment follows recommendations from the Nomination and Remuneration Committee.
Alpa Laboratories Ltd clarified to the exchanges that there is no undisclosed price-sensitive information or upcoming announcements affecting its stock performance. This response follows an exchange inquiry regarding recent price movements. The company maintains that all material events have been appropriately disclosed.